Current Classification and Management of Inflammatory Myopathies

Overview

Journal J Neuromuscul Dis

Publisher Sage Publications

Specialty Neurology

Date 2018 Jun 6

PMID 29865091

Citations 101

Authors

Jens Schmidt

Affiliations

Soon will be listed here.

Abstract

Inflammatory disorders of the skeletal muscle include polymyositis (PM), dermatomyositis (DM), (immune mediated) necrotizing myopathy (NM), overlap syndrome with myositis (overlap myositis, OM) including anti-synthetase syndrome (ASS), and inclusion body myositis (IBM). Whereas DM occurs in children and adults, all other forms of myositis mostly develop in middle aged individuals. Apart from a slowly progressive, chronic disease course in IBM, patients with myositis typically present with a subacute onset of weakness of arms and legs, often associated with pain and clearly elevated creatine kinase in the serum. PM, DM and most patients with NM and OM usually respond to immunosuppressive therapy, whereas IBM is largely refractory to treatment. The diagnosis of myositis requires careful and combinatorial assessment of (1) clinical symptoms including pattern of weakness and paraclinical tests such as MRI of the muscle and electromyography (EMG), (2) broad analysis of auto-antibodies associated with myositis, and (3) detailed histopathological work-up of a skeletal muscle biopsy. This review provides a comprehensive overview of the current classification, diagnostic pathway, treatment regimen and pathomechanistic understanding of myositis.

Citing Articles

Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort.

Ying Y, Wu T, Wang L, Zhang Y, Yu Y, Deng Z Orphanet J Rare Dis. 2025; 20(1):53.

PMID: 39915831 PMC: 11804100. DOI: 10.1186/s13023-025-03575-w.

Applicability of a serodiagnostic line blot for idiopathic inflammatory myopathy: the muscle biopsy is not all.

Fontana P, da Silva V, Corazzini R, Athayde N, Ferreira da Silva A, Brockhausen I Front Neurol. 2025; 15:1504260.

PMID: 39835155 PMC: 11743459. DOI: 10.3389/fneur.2024.1504260.

Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies.

Huang L, Huang X, Zhou W, Jiang Y, Zhu H, Lao Y J Inflamm Res. 2024; 17:9697-9710.

PMID: 39624401 PMC: 11609413. DOI: 10.2147/JIR.S490210.

Clinicopathological and imaging differences between pediatric and adult patients with anti-hydroxy-3-methyl-glutaryl-coenzyme A reductase necrotizing myopathy.

Yang M, Wang Y, Zhao Y, Yuan J, Zheng Y, Hao H Clin Rheumatol. 2024; 44(1):43-52.

PMID: 39562394 DOI: 10.1007/s10067-024-07240-8.

Imaging mimickers of MSK infection.

Taljanovic M, Omar I, Melville D, Shultz C, Klauser A, Weaver J Skeletal Radiol. 2024; 53(10):2227-2246.

PMID: 39150526 DOI: 10.1007/s00256-024-04763-8.

References

Guttsches A, Brady S, Krause K, Maerkens A, Uszkoreit J, Eisenacher M . Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2016; 81(2):227-239. PMC: 5323275. DOI: 10.1002/ana.24847. View

Harris-Love M, Joe G, Davenport T, Koziol D, Abbett Rose K, Shrader J . Reliability of the adult myopathy assessment tool in individuals with myositis. Arthritis Care Res (Hoboken). 2014; 67(4):563-70. PMC: 4450351. DOI: 10.1002/acr.22473. View

Walter M, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M . High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000; 247(1):22-8. DOI: 10.1007/s004150050005. View

Marie I . Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012; 14(3):275-85. DOI: 10.1007/s11926-012-0249-3. View

Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H . Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995; 22(4):668-74. View

Uruha A, Nishikawa A, Tsuburaya R, Hamanaka K, Kuwana M, Watanabe Y . Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017; 88(5):493-500. DOI: 10.1212/WNL.0000000000003568. View

Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J . Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015; 10:61. PMC: 4440264. DOI: 10.1186/s13023-015-0277-y. View

Lloyd T, Mammen A, Amato A, Weiss M, Needham M, Greenberg S . Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014; 83(5):426-33. PMC: 4132572. DOI: 10.1212/WNL.0000000000000642. View

Allenbach Y, Keraen J, Bouvier A, Jooste V, Champtiaux N, Hervier B . High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016; 139(Pt 8):2131-5. DOI: 10.1093/brain/aww054. View

10.

Tournadre A, Lenief V, Miossec P . Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010; 62(7):2144-51. DOI: 10.1002/art.27465. View

11.

Dalakas M . Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006; 2(8):437-47. DOI: 10.1038/ncpneuro0261. View

12.

Marie I, Hatron P, Dominique S, Cherin P, Mouthon L, Menard J . Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2011; 41(6):890-9. DOI: 10.1016/j.semarthrit.2011.09.008. View

13.

Rider L, Lachenbruch P, Monroe J, Ravelli A, Cabalar I, Feldman B . Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009; 60(11):3425-35. PMC: 2793533. DOI: 10.1002/art.24904. View

14.

Badrising U, van Duinen S, Breedveld F, van Doorn P, Van Engelen B, van den Hoogen F . Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000; 55(9):1385-7. DOI: 10.1212/wnl.55.9.1385. View

15.

Castro T, Lederman H, Terreri M, Caldana W, Zanoteli E, Hilario M . Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients. Scand J Rheumatol. 2014; 43(4):329-33. DOI: 10.3109/03009742.2013.868509. View

16.

Lloyd T, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A . Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken). 2015; 68(1):66-71. PMC: 4887848. DOI: 10.1002/acr.22600. View

17.

Rothwell S, Cooper R, Lundberg I, Gregersen P, Hanna M, Machado P . Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis Rheumatol. 2017; 69(5):1090-1099. PMC: 5516174. DOI: 10.1002/art.40045. View

18.

Rose M . 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(12):1044-55. DOI: 10.1016/j.nmd.2013.08.007. View

19.

Herbert M, Stammen-Vogelzangs J, Verbeek M, Rietveld A, Lundberg I, Chinoy H . Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis. 2015; 75(4):696-701. PMC: 4699257. DOI: 10.1136/annrheumdis-2014-206691. View

20.

Schmidt J, Dalakas M . Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn. 2013; 4(3):241-50. DOI: 10.1517/17530051003713499. View